

Early submission

Menopause (update)

Review questions

NICE guideline number tbc

Review questions

September 2023

Early submission

Developed by NICE

Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

Copyright

© NICE 2023. All rights reserved. Subject to [Notice of Rights](#).

ISBN:

Contents

Review questions	5
-------------------------------	----------

Review questions

Review topic	Review question number in the scope	Review question
[A] Cognitive behavioural therapy	1.1	What is the effectiveness of cognitive behavioural therapy for managing symptoms associated with the menopause?
[B1] Managing genitourinary symptoms (Network Meta Analysis)	1.2	What the effectiveness of treatments such as local oestrogen, ospemifene, prasterone and transvaginal laser therapy for managing genitourinary symptoms associated with the menopause?
[B2] Managing genitourinary symptoms – breast cancer recurrence	Developed after scoping	Are treatments for managing genitourinary symptoms associated with the menopause safe for women with a personal history or high inherited risk of breast cancer?
[C] Cardiovascular disease	2.1	What are the effects of hormone replacement therapy for menopausal symptoms on developing cardiovascular disease?
[D] Breast cancer	2.2	What are the effects of hormone replacement therapy for menopausal symptoms on developing breast cancer?
[E] Endometrial cancer	2.3	What are the effects of hormone replacement therapy for menopausal symptoms on developing endometrial cancer?
[F] Ovarian cancer	2.4	What are the effects of hormone replacement therapy for menopausal symptoms on developing ovarian cancer?
[G] Dementia	2.5	What are the effects of hormone replacement therapy for menopausal symptoms on developing dementia?
[H] All-cause mortality	2.6	What are the effects of hormone replacement therapy for menopausal symptoms on all-cause mortality?
[I] Early menopause	2.7	<p>What are the effects of hormone replacement therapy taken by women, non-binary and trans-masculine people with early menopause (aged 40 to 44) on all-cause mortality and developing:</p> <ul style="list-style-type: none"> • venous thromboembolism • cardiovascular disease • type 2 diabetes • breast cancer • endometrial cancer • ovarian cancer • osteoporosis • dementia • loss of muscle mass and strength?